Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/22/16  and contains information from public web pages and contributions from the ZoomInfo community.

Prof. Ulrik Ringborg

Wrong Prof. Ulrik Ringborg?

Board Member

Phone: +46 * *** ** **  HQ Phone
Email: u***@***.se
Local Address:  Stockholm , Sweden
Karolinska Institut
Solnavägen 1, Solna
Stockholm , Stockholm SE-171-77
Sweden

 
Background

Employment History

  • Head of the Oncologic Clinic
    Karolinska Hospital
  • Professor, Cancer Center Karolinska
    Karolinska Hospital
  • Head of the Department of Oncology
    Karolinska Hospital
  • President
    OECI
  • Professor At the Department of Oncology and Pathology
    Karolinska Institute
  • Professor and Cancer Expert
    Karolinska Institute
  • President
    European Society of Skin Cancer Prevention
  • Chairman
    Swedish Melanoma Study Group

Board Memberships and Affiliations

  • Board Member
    Cancer Center Karolinska
  • Executive Committee Member
    Eurocan Platform
  • Board Member
    Karolinska University Hospital Solna
  • Professor, Membership Committee Chairman
    OECI
  • Board Member
    OECI

Education

  • Karolinska Institute
  • PhD thesis , basic biology
29 Total References
Web References
EAPM - Dublin Conference Programme
supportbase.eu.com, 12 Feb 2014 [cached]
- Ulrik Ringborg
...
Prof. Ulrik Ringborg, Executive Committee Member, Eurocan Platform
...
Ulrik Ringborg Ulrik Ringborg is a Professor of Oncology, graduating from the Karolinska Institute in 1992. Since 1994 he has held the position of Director of the Cancer Centre in Karolinska. Professor Ringborg completed his PhD thesis in basic biology in 1971, graduated and received his State registration as a medical practitioner in 1972. In 1974 he joined the Department of General Oncology at Radiumhemmet and became an Associate Professor of General Oncology in 1978. He qualified as a specialist in oncology in 1979.
In 1992 he was appointed to Senior Consultant. Subsequently, he was appointed Professor of Oncology at the Karolinska Institute and Head of the Department of Oncology of Karolinska Hospital. In 1993 he became the Prefect at the Institute of Oncology-Pathology and held this position for three years. From 1996 until 2003, Ulrik was a Member of the Executive Group of the Karolinska Hospital and the following years, 2003- 2004, served as the Head of the Oncologic Clinic at the new Karolinska University Hospital.
He is a member of several committees, including Member of the Research Board and the Governing Body of the Stockholm Cancer Society, Member of the Research Board and the Governing Body of the King Gustaf V Jubilee Fund and of the Research Board and the Governing Body (Vice Chairman) of the Swedish Cancer Society.
Moreover, he was a Member of the Scientific Advisory Committee of EORTC and, at present, is a member of the Steering Group of NOCI within the EORTC. He served as a Member of the Nobel Assembly from 1993 until 2008. He was the President of European Society of Skin Cancer Prevention (2002-2003) and the President of the Organization of European Cancer Institutes (2005-2008).
Professor Ringborg has held numerous prestigious positions including Chairman of the Swedish Melanoma Study Group from 1976 to 2003, Chairman of the Investigation of Radiotherapy of Cancer from 2000 to 2003 at the Swedish Council on Technology Assessment in Healthcare and Chairman of the Development of National Guidelines for Cancer within the National Board of Health and Welfare (1998-2001).
He was awarded Honorary Membership of the Radiological Society of North America and the Hungarian Cancer Society. The author of around 280 international publications, his scientific focus is on malignant melanoma.
Oncology and Hematology Editorial Board
www.touchoncology.com, 6 Oct 2014 [cached]
Ulrik Ringborg - Professor, Cancer Center Karolinska, Karolinska University Hospital
...
Ulrik Ringborg
Professor, Cancer Center Karolinska, Karolinska University Hospital
Prof. Ringborg has authored 273 publications in international journals and books, with scientific focus on malignant melanoma.
Prof. Ringborg is a member of the Research Board and the Governing Body (Vice Chairman) of the Swedish Cancer Society. He is a member of the Scientific Advisory Committee of EORTC and a member of the Steering Group of NOCI, EORTC.
He was President of the European Society of Skin Cancer Prevention (2002-2003) and Chairman of the Advisory Board for UV-protection, Swedish Radiation Protection Authority.
Organisation of European Cancer Institues (OECI) News: Executive Board Elections 2002
oeci.uicc.org, 6 Feb 2004 [cached]
Ulrik Ringborg, Professor, M.D., Ph.D. (Sweden)
...
Ulrik Ringborg, Professor, M.D., Ph.D. (Sweden)Membership Committee Chairman
OECI Board
www.oeci-eeig.org, 18 April 2011 [cached]
Ulrik Ringborg Former President â€" OECI delegate in the CCCs Platform ulrik.ringborg@karolinska.se
Bristol-Myers Squibb And Karolinska Institute To Conduct Clinical Trials In Cancer Pharmacogenomics
www.bms.com, 8 Mar 2000 [cached]
"This type of pharmacogenomic project is not possible without collaboration with the pharmaceutical industry," said Ulrik Ringborg, professor at the Department of Oncology/Pathology, Karolinska Institute."Cancer researchers at the Cancer Centre Karolinska and Radiumhemmet are enthusiastic about the new powerful techniques for the study of human tumors.I am convinced that the program will give us new information which will improve the outcome of medical treatment of cancer patients."
The goal of the three-year collaboration, with the possibility for an extension, is to identify and validate oncology clinical markers -- genes or proteins -- that can help predict patients' responses to cancer treatment regimens.Identifying these genetic markers will ultimately allow doctors to individualize treatments for their patients with cancer in order to improve efficacy and reduce side effects.Such individualized treatment could boost favorable response rates to as high as 70-90 percent.
...
For more information, contact: William Dunnett, Bristol-Myers Squibb, 609-252-3369, or Professor Ulrik Ringborg, Department of Oncology/Pathology, Karolinska Institute
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304